Codexis, Inc. (CDXS): Price and Financial Metrics


Codexis, Inc. (CDXS): $10.10

0.14 (+1.41%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add CDXS to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

CDXS POWR Grades


  • Momentum is the dimension where CDXS ranks best; there it ranks ahead of 62.7% of US stocks.
  • CDXS's strongest trending metric is Growth; it's been moving down over the last 179 days.
  • CDXS's current lowest rank is in the Growth metric (where it is better than 3.37% of US stocks).

CDXS Stock Summary

  • CDXS's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 594.82 -- higher than 95.29% of US-listed equities with positive expected earnings growth.
  • With a price/sales ratio of 13.17, Codexis Inc has a higher such ratio than 88.9% of stocks in our set.
  • With a year-over-year growth in debt of 90.99%, Codexis Inc's debt growth rate surpasses 89.01% of about US stocks.
  • If you're looking for stocks that are quantitatively similar to Codexis Inc, a group of peers worth examining would be BYSI, NPTN, KPTI, ALBO, and DYAI.
  • Visit CDXS's SEC page to see the company's official filings. To visit the company's web site, go to www.codexis.com.

CDXS Valuation Summary

  • In comparison to the median Healthcare stock, CDXS's price/earnings ratio is 304.93% lower, now standing at -74.8.
  • Over the past 138 months, CDXS's price/sales ratio has gone up 15.7.
  • CDXS's price/sales ratio has moved up 15.7 over the prior 138 months.

Below are key valuation metrics over time for CDXS.

Stock Date P/S P/B P/E EV/EBIT
CDXS 2021-08-31 21.1 10.7 -74.8 -70.3
CDXS 2021-08-30 20.6 10.5 -73.1 -68.6
CDXS 2021-08-27 20.8 10.6 -73.8 -69.3
CDXS 2021-08-26 19.8 10.1 -70.2 -65.6
CDXS 2021-08-25 20.2 10.3 -71.8 -67.3
CDXS 2021-08-24 19.2 9.8 -68.2 -63.7

CDXS Growth Metrics

    The 4 year net cashflow from operations growth rate now stands at -407.23%.
  • Its 5 year net cashflow from operations growth rate is now at -407.23%.
  • Its 5 year cash and equivalents growth rate is now at 287.87%.
CDXS's revenue has moved up $42,619,000 over the prior 34 months.

The table below shows CDXS's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 104.754 -14.267 -21.279
2021-09-30 101.287 -16.419 -15.009
2021-06-30 82.903 -19.701 -23.347
2021-03-31 72.417 -21.479 -25.426
2020-12-31 69.056 -16.464 -24.01
2020-09-30 66.672 -18.633 -20.725

CDXS's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • CDXS has a Quality Grade of C, ranking ahead of 53.6% of graded US stocks.
  • CDXS's asset turnover comes in at 0.423 -- ranking 65th of 89 Chemicals stocks.
  • NGVT, GPP, and IFF are the stocks whose asset turnover ratios are most correlated with CDXS.

The table below shows CDXS's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.423 0.782 -0.333
2021-03-31 0.406 0.787 -0.370
2020-12-31 0.424 0.801 -0.359
2020-09-30 0.461 0.831 -0.313
2020-06-30 0.479 0.819 -0.220
2020-03-31 0.457 0.796 -0.237

CDXS Price Target

For more insight on analysts targets of CDXS, see our CDXS price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $29.50 Average Broker Recommendation 1.31 (Strong Buy)

CDXS Stock Price Chart Interactive Chart >

Price chart for CDXS

CDXS Price/Volume Stats

Current price $10.10 52-week high $42.01
Prev. close $9.96 52-week low $9.47
Day low $9.95 Volume 1,260,100
Day high $10.54 Avg. volume 843,766
50-day MA $15.43 Dividend yield N/A
200-day MA $24.09 Market Cap 659.57M

Codexis, Inc. (CDXS) Company Bio


Codexis, Inc. develops biocatalysts for the pharmaceutical and fine chemicals markets in the United States and internationally. The company offers Codex biocatalyst panels and kits to pharmaceutical companies that are engaged in drug development and the marketing of approved drugs to allow them to screen and identify possible enzymatic manufacturing processes for their drug candidates and their marketed products. The company was founded in 2002 and is based in Redwood City, California.


CDXS Latest News Stream


Event/Time News Detail
Loading, please wait...

CDXS Latest Social Stream


Loading social stream, please wait...

View Full CDXS Social Stream

Latest CDXS News From Around the Web

Below are the latest news stories about Codexis Inc that investors may wish to consider to help them evaluate CDXS as an investment opportunity.

Codexis to Participate in the Cowen 42nd Annual Health Care Conference

REDWOOD CITY, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq:CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that management will participate in both a panel discussion and a fireside chat at the Cowen 42 nd Annual Health Care Conference, being held virtually March 7-9, 2022.

GlobeNewswire | March 1, 2022

Growth Investors: Industry Analysts Just Upgraded Their Codexis, Inc. (NASDAQ:CDXS) Revenue Forecasts By 16%

Codexis, Inc. ( NASDAQ:CDXS ) shareholders will have a reason to smile today, with the analysts making substantial...

Yahoo | February 27, 2022

Codexis, Inc. 2021 Q4 - Results - Earnings Call Presentation

No summary available.

Seeking Alpha | February 25, 2022

Codexis, Inc. (CDXS) CEO John Nicols on Q4 2021 Results - Earnings Call Transcript

No summary available.

Seeking Alpha | February 24, 2022

Codexis GAAP EPS of -$0.16 beats by $0.04, revenue of $24.5M beats by $1.35M

Codexis press release (CDXS): Q4 GAAP EPS of -$0.16 beats by $0.04.Revenue of $24.5M (+16.7% Y/Y) beats by $1.35M.Outlook: Company Guides to 2022 Total Revenues of…

Seeking Alpha | February 24, 2022

Read More 'CDXS' Stories Here

CDXS Price Returns

1-mo -18.15%
3-mo -49.63%
6-mo -72.42%
1-year -50.44%
3-year -47.40%
5-year 134.88%
YTD -67.70%
2021 43.24%
2020 36.52%
2019 -4.25%
2018 100.00%
2017 81.52%

Continue Researching CDXS

Here are a few links from around the web to help you further your research on Codexis Inc's stock as an investment opportunity:

Codexis Inc (CDXS) Stock Price | Nasdaq
Codexis Inc (CDXS) Stock Quote, History and News - Yahoo Finance
Codexis Inc (CDXS) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.5232 seconds.